Poxviruses

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Damon, Inger K ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974710222     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (215)

1. Abrahao JS, Guedes MI, Trindade GS, et al. One more piece in the VACV ecological puzzle: could peridomestic rodents be the link between wildlife and bovine vaccinia outbreaks in Brazil? PLoS One 2009;4:e7428.
2. Alcami A, Smith GL. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 1992;71:153-167.
3. Alejo A, Pontejo SM, Alcami A. Poxviral TNFRs: properties and role in viral pathogenesis. Adv Exp Med Biol 2011;691:203-210.
4. Amara RR, Nigam P, Sharma S, et al. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 2004;78:3811-3816.
5. Anderson IE, Reid HW, Nettleton PF, et al. Detection of cellular cytokine mRNA expression during orf virus infection in sheep: differential interferon-gamma mRNA expression by cells in primary versus reinfection skin lesions. Vet Immunol Immunopathol 2001;83:161-176.
6. Andrew ME, Coupar BE. Biological effects of recombinant vaccinia virus-expressed interleukin 4. Cytokine 1992;4:281-286.
7. Babiuk S, Bowden TR, Boyle DB, et al. Capripoxviruses: an emerging worldwide threat to sheep, goats and cattle. Transbound Emerg Dis 2008;55:263-272.
8. Barrett JW, Cao JX, Hota-Mitchell S, et al. Immunomodulatory proteins of myxoma virus. Semin Immunol 2001;13:73-84.
9. Barrett JW, McFadden G, eds. Genus Leporipoxvirus. Birkhauser, Basel; 2007.
10. Baxby D. The origins of vaccinia virus. J Infect Dis 1977;136:453-455.
11. Baxby D, Bennett M. Poxvirus zoonoses. J Med Microbiol 1997;46:17-20, 28-33.
12. Baxby D, Bennett M, Getty B. Human cowpox 1969-1993: a review based on 54 cases. Br J Dermatol 1994;131:598-607.
13. Beattie E, Kauffman EB, Martinez H, et al. Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes 1996;12:89-94.
14. Becher P, Konig M, Muller G, et al. Characterization of sealpox virus, a separate member of the parapoxviruses. Arch Virol 2002;147:1133-1140.
15. Becker Y. Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity. Virus Genes 2003;27:269-282.
16. Bennett M, Crouch AJ, Begon M, et al. Cowpox in British voles and mice. J Comp Pathol 1997;116:35-44.
17. Bennett M, Gaskell CJ, Gaskell RM, et al. Poxvirus infection in the domestic cat: some clinical and epidemiological observations. Vet Rec 1986;118:387-390.
18. Bera BC, Shanmugasundaram K, Barua S, et al. Zoonotic cases of camelpox infection in India. Vet Microbiol 2011;152:29-38.
19. Best SM, Kerr PJ. Coevolution of host and virus: the pathogenesis of virulent and attenuated strains of myxoma virus in resistant and susceptible European rabbits. Virology 2000;267:36-48.
20. Birthistle K, Carrington D. Molluscum contagiosum virus. J Infect 1997;34:21-28.
21. Bolken TC, Hruby DE. Tecovirimat for smallpox infections. Drugs Today (Barc) 2010;46:109-117.
22. Boyle D, ed. Genus Avipoxvirus. Birkhauser, Basel; 2007.
23. Bras G. The morbid anatomy of smallpox. Doc Med Geogr Trop 1952;4(4):303-351.
24. Bray M, Wright ME. Progressive vaccinia. Clin Infect Dis 2003;36:766-774.
25. Brum LM, Lopez MC, Varela JC, et al. Microarray analysis of A549 cells infected with rabbitpox virus (RPV): a comparison of wild-type RPV and RPV deleted for the host range gene, SPI-1. Virology 2003;315:322-334.
26. Brunetti CR, Paulose-Murphy M, Singh R, et al. A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc Natl Acad Sci U S A 2003;100:4831-4836.
27. Buddle BM, Pulford HD. Effect of passively-acquired antibodies and vaccination on the immune response to contagious ecthyma virus. Vet Microbiol 1984;9:515-522.
28. Buller RM, Palumbo GJ. Poxvirus pathogenesis. Microbiol Rev 1991;55:80-122.
29. Campe H, Zimmermann P, Glos K, et al. Cowpox virus transmission from pet rats to humans, Germany. Emerg Infect Dis 2009;15:777-780.
30. Carroll D, Emerson G. Chasing Jenner's vaccine. PLoS One 2011;6(8):e23086.
31. Carslake D, Bennett M, Hazel S, et al. Inference of cowpox virus transmission rates between wild rodent host classes using space-time interaction. Proc Biol Sci 2006;273:775-782.
32. Carson CA, Kerr KM, Grumbles LC. Bovine papular stomatitis: experimental transmission from man. Am J Vet Res 1968;29:1783-1790.
33. Centers for Disease Control and Prevention (CDC). Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2009;58:1204-1207.
34. Centers for Disease Control and Prevention (CDC). Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep 2009;58:532-536.
35. Chantrey J, Meyer H, Baxby D, et al. Cowpox: reservoir hosts and geographic range. Epidemiol Infect 1999;122:455-460.
36. Chapman JL, Nichols DK, Martinez MJ, et al. Animal models of orthopoxvirus infection. Vet Pathol 2010;47:852-870.
37. Chaudhri G, Panchanathan V, Bluethmann H, et al. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 2006;80:6339-6344.
38. Chaudhri G, Panchanathan V, Buller RM, et al. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A 2004;101:9057-9062.
39. Chen N, Li G, Liszewski MK, et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 2005;340:46-63.
40. Coloe J, Burkhart CN, Morrell DS. Molluscum contagiosum: what's new and true? Pediatr Ann 2009;38:321-325.
41. Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003;52:1-28.
42. Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171:4969-4973.
43. Czerny CP, Waldmann R, Scheubeck T. Identification of three distinct antigenic sites in parapoxviruses. Arch Virol 1997;142:807-821.
44. da Fonseca FG, Trindade GS, Silva RL, et al. Characterization of a vaccinia-like virus isolated in a Brazilian forest. J Gen Virol 2002;83:223-228.
45. Damon I. Poxviruses that infect humans. In: Murray PJ, Baron EJ, Jorgensen G, et al, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press; 2011: 1647-1658.
46. Davies FG. Lumpy skin disease, an African capripox virus disease of cattle. Br Vet J 1991;147:489-503.
47. de Souza Trindade G, da Fonseca FG, Marques JT, et al. Aracatuba virus: a vaccinialike virus associated with infection in humans and cattle. Emerg Infect Dis 2003;9:155-160.
48. de Souza Trindade G, Drumond BP, Guedes MI, et al. Zoonotic vaccinia virus infection in Brazil: clinical description and implications for health professionals. J Clin Microbiol 2007;45:1370-1372.
49. Delhon G, Tulman ER, Afonso CL, et al. Genomes of the parapoxviruses ORF virus and bovine papular stomatitis virus. J Virol 2004;78:168-177.
50. Dhar AD, Werchniak AE, Li Y, et al. Tanapox infection in a college student. N Engl J Med 2004;350:361-366.
51. DiPerna G, Stack J, Bowie AG, et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 2004;279:36570-36578.
52. Downie AW. The epidemiology of tanapox and yaba virus infections. J Med Microbiol 1972;5:Pxiv.
53. Downie AW, Espana C. Comparison of Tanapox virus and Yaba-like viruses causing epidemic disease in monkeys. J Hyg (Lond) 1972;70:23-32.
54. Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005;11:740-747.
55. Esposito JJ, Sammons SA, Frace AM, et al. Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science 2006;313:807-812.
56. Esteban DJ, Buller RM. Ectromelia virus: the causative agent of mousepox. J Gen Virol 2005;86:2645-2659.
57. Fang M, Lanier LL, Sigal LJ. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog 2008;4:e30.
58. Fenner F. Studies in infectious ectromelia virus. II. Natural transmission: the portal of entry of the virus. Aust J Exp Biol Med Sci 1947;25:275-282.
59. Fenner F, Henderson DA, Arita I, et al. Smallpox and its Eradication. Geneva: World Health Organization; 1988.
60. Fenner F, Ratcliffe FN. Myxomatosis. London: Cambridge University Press; 1965.
61. Fenner F, Wittek R, Dumbell K. The Pathogenesis, Pathology, and Immunology of Orthopoxvirus Infections: The Orthopoxviruses. New York: Academic Press; 1989.
62. Fischer MA, Norbury CC. Initiation of primary anti-vaccinia virus immunity in vivo. Immunol Res 2007;37:113-133.
63. Fleming SB, Anderson IE, Thomson J, et al. Infection with recombinant orf viruses demonstrates that the viral interleukin-10 is a virulence factor. J Gen Virol 2007;88:1922-1927.
64. Fulginiti VA, Papier A, Lane JM, et al. Smallpox vaccination: A review, part II. Adverse events. Clin Infect Dis 2003;37:251-271.
65. Goff AJ, Chapman J, Foster C, et al. A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J Virol 2011;85:4898-4909.
66. Gottlieb SL, Myskowski PL. Molluscum contagiosum. Int J Dermatol 1994;33:453-461.
67. Grace JT Jr, Mirand EA. Yaba virus infection in humans. Exp Med Surg 1965;23:213-216.
68. Greene HSN. Rabbitpox. II. Pathology of the epidemic disease. J Exp Med 1934;60(4):441-455.
69. Groppel KH. The occurence of ectromelia (mousepox)in wild mice. Arch Exp Vet 1962;16:243-278.
70. Gubser C, Hue S, Kellam P, et al. Poxvirus genomes: a phylogenetic analysis. J Gen Virol 2004;85:105-117.
71. Gubser C, Smith GL. The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J Gen Virol 2002;83:855-872.
72. Guerra S, Lopez-Fernandez LA, Conde R, et al. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 2004;78:5820-5834.
73. Hahon N. Smallpox and related poxvirus infections in the simian host. Bacteriol Rev 1961;25:459-476.
74. Haig DM, McInnes CJ. Immunity and counter-immunity during infection with the parapoxvirus orf virus. Virus Res 2002;88:3-16.
75. Hall AS, McNulty WP Jr. A contagious pox disease in monkeys. J Am Vet Med Assoc 1967;151:833-838.
76. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003;289:3283-3289.
77. Hammarlund E, Lewis MW, Hanifin JM, et al. Antiviral immunity following smallpox virus infection: a case-control study. J Virol 2010;84:12754-12760.
78. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9:1131-1137.
79. Hayasaka D, Ennis FA, Terajima M. Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses. Virol J 2007;4:22.
80. Heiner GG, Fatima N, McCrumb FR Jr. A study of intrafamilial transmission of smallpox. Am J Epidemiol 1971;94:316-326.
81. Hicks BD, Worthy GA. Sealpox in captive grey seals (Halichoerus grypus) and their handlers. J Wildl Dis 1987;23:1-6.
82. Hoebe K, Du X, Georgel P, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003;424:743-748.
83. Horner GW, Robinson AJ, Hunter R, et al. Parapoxvirus infections in New Zealand farmed red deer (Cervus elaphus). N Z Vet J 1987;35:41-45.
84. Howell MD, Gallo RL, Boguniewicz M, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006;24:341-348.
85. Howell MD, Jones JF, Kisich KO, et al. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 2004;172:1763-1767.
86. Huggins J, Goff A, Hensley L, et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 2009;53:2620-2625.
87. Hunter P, Wallace D. Lumpy skin disease in southern Africa: a review of the disease and aspects of control. J S Afr Vet Assoc 2001;72:68-71.
88. Hutin YJ, Williams RJ, Malfait P, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 2001;7:434-438.
89. Hutson CL, Damon IK. Monkeypox virus infections in small animal models for evaluation of anti-poxvirus agents. Viruses 2010;2:2763-2776.
90. Hutson CL, Olson VA, Carroll DS, et al. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol 2009;90:323-333.
91. Inoshima Y, Morooka A, Sentsui H. Detection and diagnosis of parapoxvirus by the polymerase chain reaction. J Virol Methods 2000;84:201-208.
92. Jackson RJ, Ramsay AJ, Christensen CD, et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001;75:1205-1210.
93. Jahrling PB, Hensley LE, Martinez MJ, et al. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A 2004;101:15196-15200.
94. Jenner E. An enquiry into the causes and effects of variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucerstershire, and known by the name of cowpox. London; 1798.
95. Jezek Z, Arita I, Szczeniowski M, et al. Human tanapox in Zaire: clinical and epidemiological observations on cases confirmed by laboratory studies. Bull World Health Organ 1985;63:1027-1035.
96. Jezek Z, Fenner F. Human Monkeypox. Vol. 1. New York: Karger; 1988.
97. Jezek Z, Kriz B, Rothbauer V. Camelpox and its risk to the human population. J Hyg Epidemiol Microbiol Immunol 1983;27:29-42.
98. Johannessen JV, Krogh HK, Solberg I, et al. Human orf. J Cutan Pathol 1975;2:265-283.
99. Johnston JB, McFadden G. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol 2004;6:695-705.
100. Karem KL, Reynolds M, Braden Z, et al. characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol 2005;12:867-872.
101. Karem KL, Reynolds M, Hughes C, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol 2007;14:1318-1327.
102. Karupiah G, Buller RM, Van Rooijen N, et al. Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol 1996;70:8301-8309.
103. Karupiah G, Panchanathan V, Sakala IG, et al. Genetic resistance to smallpox: lessons from mousepox. Novartis Found Symp 2007;281:129-136; discussion 136-140, 208-219.
104. Keidan SE, McCarthy K, Haworth JC. Fatal generalized vaccinia with failure of antibody production and absence of serum gamma globulin. Arch Dis Child 1953;28:110-116.
105. Kelly CD, Egan C, Davis SW, et al. Laboratory confirmation of generalized vaccinia following smallpox vaccination. J Clin Microbiol 2004;42:1373-1375.
106. Kempe CH. Studies smallpox and complications of smallpox vaccination. Pediatrics 1960;26:176-189.
107. Kennedy RB, Ovsyannikova IG, Jacobson RM, et al. The immunology of smallpox vaccines. Curr Opin Immunol 2009;21:314-320.
108. Kern ER. In vitro activity of potential anti-poxvirus agents. Antiviral Res 2003;57:35-40.
109. Kibler KV, Shors T, Perkins KB, et al. Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J Virol 1997;71:1992-2003.
110. Klein J, Tryland M. Characterisation of parapoxviruses isolated from Norwegian semi-domesticated reindeer (Rangifer tarandus tarandus). Virol J 2005;2:79.
111. Knight JC, Goldsmith CS, Tamin A, et al. Further analyses of the orthopoxviruses volepox virus and raccoon poxvirus. Virology 1992;190:423-433.
112. Knight JC, Novembre FJ, Brown DR, et al. Studies on Tanapox virus. Virology 1989;172:116-124.
113. Kolhapure RM, Deolankar RP, Tupe CD, et al. Investigation of buffalopox outbreaks in Maharashtra State during 1992-1996. Indian J Med Res 1997;106:441-446.
114. Koplan JP, Marton KI. Smallpox vaccination revisited. Some observations on the biology of vaccinia. Am J Trop Med Hyg 1975;24:656-663.
115. Kurth A, Nitsche A. Detection of human-pathogenic poxviruses. Methods Mol Biol 2011;665:257-278.
116. Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-1208.
117. Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the Treatment of Poxvirus Infections. Viruses 2010;2:2740-2762.
118. Lateef Z, Baird MA, Wise LM, et al. The chemokine-binding protein encoded by the poxvirus orf virus inhibits recruitment of dendritic cells to sites of skin inflammation and migration to peripheral lymph nodes. Cell Microbiol 2010;12:665-676.
119. Lateef Z, Fleming S, Halliday G, et al. Orf virus-encoded interleukin-10 inhibits maturation, antigen presentation and migration of murine dendritic cells. J Gen Virol 2003;84:1101-1109.
120. Learned LA, Reynolds MG, Wassa DW, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 2005;73:428-434.
121. Leavell UW Jr, McNamara MJ, Muelling R, et al. Orf. Report of 19 human cases with clinical and pathological observations. JAMA 1968;204:657-664.
122. Lee SB, Esteban M. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology 1994;199:491-496.
123. Leite JA, Drumond BP, Trindade GS, et al. Passatempo virus, a vaccinia virus strain, Brazil. Emerg Infect Dis 2005;11:1935-1938.
124. Li Y, Carroll DS, Gardner SN, et al. On the origin of smallpox: correlating variola phylogenics with historical smallpox records. Proc Natl Acad Sci U S A 2007;104:15787-15792.
125. Li Y, Meyer H, Zhao H, et al. GC content-based pan-pox universal PCR assays for poxvirus detection. J Clin Microbiol 2010;48:268-276.
126. Li Y, Olson VA, Laue T, et al. Detection of monkeypox virus with real-time PCR assays. J Clin Virol 2006;36:194-203.
127. Likos AM, Sammons SA, Olson VA, et al. A tale of two clades: monkeypox viruses. J Gen Virol 2005;86:2661-2672.
128. Lipschutz B, ed. Handbuch der Haut und Geschlechtskrankenheiten. Berlin: Springer; 1932.
129. Livingston CW, Hardy WT. Longevity of contagious ecthyma virus. J Am Vet Med Assoc 1960;137:651.
130. Lloyd JB, Gill HS, Haig DM, et al. In vivo T-cell subset depletion suggests that CD4+ T-cells and a humoral immune response are important for the elimination of orf virus from the skin of sheep. Vet Immunol Immunopathol 2000;74:249-262.
131. Lourie B, Nakano JH, Kemp GE, et al. Isolation of poxvirus from an African Rodent. J Infect Dis 1975;132:677-681.
132. Luker KE, Hutchens M, Schultz T, et al. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 2005;341:284-300.
133. Marchal, J. Infectious ectromelia. J Pathol Bacteriol 1930;33:713-728.
134. Marennikova SS, Maltseva NN, Korneeva VI, et al. Outbreak of pox disease among carnivora (felidae) and edentata. J Infect Dis 1977;135:358-366.
135. Martinez MJ, Bray MP, Huggins JW. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch Pathol Lab Med 2000;124:362-377.
136. Massoudi MS, Barker L, Schwartz B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. J Infect Dis 2003;188:973-976.
137. McCabe D, Weston B, Storch G. Treatment of orf poxvirus lesion with cidofovir cream. Pediatr Infect Dis J 2003;22:1027-1028.
138. McCurdy LH, Larkin BD, Martin JE, et al. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 2004;38:1749-1753.
139. McFadden G. Poxvirus tropism. Nat Rev Microbiol 2005;3:201-213.
140. McKeever DJ, Jenkinson DM, Hutchison G, et al. Studies of the pathogenesis of orf virus infection in sheep. J Comp Pathol 1988;99:317-328.
141. Mellor PS, Kitching RP, Wilkinson PJ. Mechanical transmission of capripox virus and African swine fever virus by Stomoxys calcitrans. Res Vet Sci 1987;43:109-112.
142. Mercer AA, Ueda N, Friederichs SM, et al. Comparative analysis of genome sequences of three isolates of Orf virus reveals unexpected sequence variation. Virus Res 2006;116:146-158.
143. Meseda CA, Mayer AE, Kumar A, et al. Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin Vaccine Immunol 2009;16:1261-1271.
144. Mohamed MR, McFadden G. NFkB inhibitors: strategies from poxviruses. Cell Cycle 2009;8:3125-3132.
145. Moss, B. Poxvirus entry and membrane fusion. Virology 2006;344:48-54.
146. Nakamura J, Muraki Y, Yamada M, et al. Analysis of molluscum contagiosum virus genomes isolated in Japan. J Med Virol 1995;46:339-348.
147. Nalca A, Livingston VA, Garza NL, et al. Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus. PLoS One 2010;5(9):e12880.
148. Nawathe DR, Gibbs EP, Asagba MO, et al. Lumpyskin disease in Nigeria. Trop Anim Health Prod 1978;10:49-54.
149. Nell P, Kohl KS, Graham PL, et al. Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5725-5734.
150. Nell P, Kohl KS, Graham PL, et al. Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5735-5744.
151. Niven JS, Armstrong JA, Andrewes CH, et al. Subcutaneous "growths" in monkeys produced by a poxvirus. J Pathol Bacteriol 1961;81:1-14.
152. Olson C Jr, Palionis T. The transmission of proliferative stomatitis of cattle. J Am Vet Med Assoc 1953;123:419-426.
153. Olson VA, Laue T, Laker MT, et al. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol 2004;42:1940-1946.
154. Panchanathan V, Chaudhri G, Karupiah G. Antiviral protection following immunization correlates with humoral but not cell-mediated immunity. Immunol Cell Biol 2010;88:461-467.
155. Panchanathan V, Chaudhri G, Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc Natl Acad Sci U S A 2005;102:12921-12926.
156. Perkus ME, Goebel SJ, Davis SW, et al. Vaccinia virus host range genes. Virology 1990;179:276-286.
157. Pierard-Franchimont C, Legrain A, Pierard GE. Growth and regression of molluscum contagiosum. J Am Acad Dermatol 1983;9:669-672.
158. Pilaski J, Rosen A, Darai G. Comparative analysis of the genomes of orthopoxviruses isolated from elephant, rhinoceros, and okapi by restriction enzymes. Brief report. Arch Virol 1986;88:135-142.
159. Pilaski J, Rosen-Wolff A. Poxvirus infection in zoo-kept mammals. Virus Diseases in Captive and Laboratory Animals. Boston: Martenjus-Nijhoff; 1988:84-100.
160. Pogo BG, Melana SM, Blaho J. Poxvirus infection and apoptosis. Int Rev Immunol 2004;23:61-74.
161. Postlethwaite R. Molluscum contagiosum. Arch Environ Health 1970;21:432-452.
162. Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Anti{reversed not sign}microb Agents Chemother 2007;51:4118-4124.
163. Ramshaw IA, Ramsay AJ, Karupiah G, et al. Cytokines and immunity to viral infections. Immunol Rev 1997;159:119-135.
164. Rao TV, Bandyopadhyay SK. A comprehensive review of goat pox and sheep pox and their diagnosis. Anim Health Res Rev 2000;1:127-136.
165. Reeves PM, Bommarius B, Lebeis S, et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005;11:731-739.
166. Reeves PM, Smith SK, Olson VA, et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol 2011;85:21-31.
167. Regnery DC. Isolation and partial characterization of an orthopoxvirus from a California vole (Microtus californicus). Brief report. Arch Virol 1987;94:159-162.
168. Reynolds MG, Yorita KL, Kuehnert MJ, et al. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis 2006;194:773-780.
169. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 2010;107:16262-16267.
170. Roberts JA. Histopathogenesis of mousepox. I. Respiratory infection. Br J Exp Pathol 1962;43:451-461.
171. Roberts JA. Histopathogenesis of mousepox. II. Cutaneous infection. Br J Exp Pathol 1962;43:462-468.
172. Roberts KL, Smith GL. Vaccinia virus morphogenesis and dissemination. Trends Microbiol 2008;16:472-479.
173. Robinson AJ, Mercer AA. Parapoxvirus of red deer: evidence for its inclusion as a new member in the genus parapoxvirus. Virology 1995;208:812-815.
174. Robinson AJ, Petersen GV. Orf virus infection of workers in the meat industry. N Z Med J 1983;96:81-85.
175. Rodriguez JR, Rodriguez D, Esteban M. Interferon treatment inhibits early events in vaccinia virus gene expression in infected mice. Virology 1991;185:929-933.
176. Roess AA, Galan A, Kitces E, et al. Novel deer-associated parapoxvirus infection in deer hunters. N Engl J Med 2010;363:2621-2627.
177. Rotz L, Dotson DA, Damon I, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Commitee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001;50:1-25.
178. Ruben FL, Lane JM. Ocular vaccinia. An epidemiologic analysis of 348 cases. Arch Ophthalmol 1970;84:45-48.
179. Rubins KH, Hensley LE, Jahrling PB, et al. The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A 2004;101:15190-15195.
180. Sanderson CM, Smith GL. Vaccinia virus induces Ca2+-independent cell-matrix adhesion during the motile phase of infection. J Virol 1998;72:9924-9933.
181. Sarkar JK, Mitra AC, Chakravarty MS. Relationship of clinical severity, antibody level, and previous vaccination state in smallpox. Trans R Soc Trop Med Hyg 1972;66:789-792.
182. Sarkar JK, Mitra AC, Mukherjee MK, et al. Isolation of virus from the urine, conjunctiva and throat of smallpox cases. Bull Calcutta Sch Trop Med 1972;20:37-39.
183. Sarkar JK, Mitra AC, Mukherjee MK, et al. Virus excretion in smallpox. 1. Excretion in the throat, urine, and conjunctiva of patients. Bull World Health Organ 1973;48:517-522.
184. Savory LJ, Stacker SA, Fleming SB, et al. Viral vascular endothelial growth factor plays a critical role in orf virus infection. J Virol 2000;74:10699-10706.
185. Schroeder K, Nitsche A. Multicolour, multiplex real-time PCR assay for the detection of human-pathogenic poxviruses. Mol Cell Probes 2010;24:110-113.
186. Seet BT, Johnston JB, Brunetti CR, et al. Poxviruses and immune evasion. Annu Rev Immunol 2003;21:377-423.
187. Sejvar JJ, Chowdary Y, Schomogyi M, et al. Human monkeypox infection: a family cluster in the midwestern United States. J Infect Dis 2004;190:1833-1840.
188. Senkevich TG, Bugert JJ, Sisler JR, et al. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 1996;273:813-816.
189. Seward JF, Galil K, Damon I, et al. Development and experience with an algorithm to evaluate suspected smallpox cases in the United States, 2002-2004. Clin Infect Dis 2004;39:1477-1483.
190. Sharma DP, Ramsay AJ, Maguire DJ, et al. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 1996;70:7103-7107.
191. Shisler JL, Jin XL. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J Virol 2004;78:3553-3560.
192. Stack J, Haga IR, Schroder M, et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 2005;201:1007-1018.
193. Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007;68:S23-S36.
194. Thomas K, Tompkins DM, Sainsbury AW, et al. A novel poxvirus lethal to red squirrels (Sciurus vulgaris). J Gen Virol 2003;84:3337-3341.
195. Thompson CH. Identification and typing of molluscum contagiosum virus in clinical specimens by polymerase chain reaction. J Med Virol 1997;53:205-211.
196. Torfason EG, Gunadottir S. Polymerase chain reaction for laboratory diagnosis of orf virus infections. J Clin Virol 2002;24:79-84.
197. Trindade GS, da Fonseca FG, Marques JT, et al. Belo Horizonte virus: a vaccinia-like virus lacking the A-type inclusion body gene isolated from infected mice. J Gen Virol 2004;85:2015-2021.
198. Tryland M, Klein J, Nordoy ES, et al. Isolation and partial characterization of a parapoxvirus isolated from a skin lesion of a Weddell seal. Virus Res 2005;108:83-87.
199. Tscharke DC, Reading PC, Smith GL. Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 2002;83:1977-1986.
200. Vellozzi C, Lane JM, Averhoff F, et al. Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003. Clin Infect Dis 2005;41:689-697.
201. Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008;46:1555-1561.
202. Voss TG, Roy CJ. Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents. Viruses 2010;2:2096-2107.
203. Wallace GD, Werner RM, Golway PL, et al. Epizootiology of an outbreak of mousepox at the National Institutes of Health. Lab Anim Sci 1981;31:609-615.
204. Wasilenko ST, Banadyga L, Bond D, et al. The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation. J Virol 2005;79:14031-14043.
205. Werden SJ, Rahman MM, McFadden G. Poxvirus host range genes. Adv Virus Res 2008;71:135-171.
206. Wernery U, Zachariah R. Experimental camelpox infection in vaccinated and unvaccinated dromedaries. Zentralbl Veterinarmed B 1999;46:131-135.
207. Westwood JC, Boulter EA, Bowen ET, et al. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol 1966;47:453-465.
208. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-5545.
209. Wilson TM, Cheville NF, Karstad L. Seal pox. Case history. Wildl Dis 1969;5:412-418.
210. Xu RH, Cohen M, Tang Y, et al. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J Exp Med 2008;205:981-992.
211. Yirrell DL, Vestey JP, Norval M. Immune responses of patients to orf virus infection. Br J Dermatol 1994;130:438-443.
212. Young E, Basson PA, Weiss KE. Experimental infection of game animals with lumpy skin disease virus (prototype strain Neethling). Onderstepoort J Vet Res 1970;37:79-87.
213. Zaucha GM, Jahrling PB, Geisbert TW, et al. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2001;81:1581-1600.
214. Zimmermann P, Thordsen I, Frangoulidis D, et al. Real-time PCR assay for the detection of tanapox virus and yaba-like disease virus. J Virol Methods 2005;130:149-153.
215. Zuniga MC. A pox on thee! Manipulation of the host immune system by myxoma virus and implications for viral-host co-adaptation. Virus Res 2002;88:17-33.